Diagnostic delay remains a critical challenge in axial spondyloarthritis (axSpA). This review highlights key clinical and imaging research from 2024 that addresses this persistent issue, with a focus on the evolving roles of MRI, artificial intelligence (AI), and updated Canadian management recommendations. Multiple studies published in 2024 emphasized the continued problem of diagnostic delay in axSpA. Studies support the continued use of sacroiliac joint MRI as a central diagnostic tool for axSpA, particularly in patients with chronic back pain and associated conditions like uveitis, psoriasis (PsO), or inflammatory bowel disease. AI-based tools for interpreting sacroiliac joint MRIs demonstrated moderate agreement with expert assessments, offering a potential solution to variability and limited access to expert musculoskeletal radiology. These innovations may support earlier diagnosis and reduce misclassification. Innovative models of care, including patient-initiated telemedicine visits, reduced in-person visit frequency without compromising clinical outcomes in patients with stable axSpA. Updated Canadian treatment guidelines introduced more robust data on Janus kinase (JAK) inhibitors and offered stronger support for tapering biologics in patients with sustained low disease activity or remission, while advising against abrupt discontinuation. This clinical and imaging year in review covers challenges and innovations in axSpA, emphasizing the need for early access to care and the development of tools to support prompt diagnosis and sustained continuity of care.

MR neurography sequences provide excellent nerve-to-background soft tissue contrast, whereas a zero echo time (ZTE) MRI sequence provides cortical bone contrast. By demonstrating the spatial relationship between nerves and bones, a combination of rendered three-dimensional (3D) MR neurography and ZTE sequences provides a roadmap for clinical decision-making, particularly for surgical intervention. In this article, the authors describe the method for fused rendering of peripheral nerve and bone by combining nerve and bone structures from 3D MR neurography and 3D ZTE MRI, respectively. The described method includes scanning acquisition, postprocessing that entails deep learning-based reconstruction techniques, and rendering techniques. Representative case examples demonstrate the steps and clinical use of these techniques. Challenges in nerve and bone rendering are also discussed.

Interstitial lung disease (ILD) diagnosis is complex, continuously evolving, and increasingly reliant on thin-section chest CT. Multidisciplinary discussion aided by a thorough radiologic review can achieve a high-confidence diagnosis of ILD in the majority of patients and is currently the reference standard for ILD diagnosis. CT also allows the early recognition of interstitial lung abnormalities, possibly reflective of unsuspected ILD and progressive in a substantial proportion of patients. Beyond diagnosis, CT has also become essential for ILD prognostication and follow-up, aiding the identification of fibrotic and progressive forms. The presence of fibrosis is a critical determinant of prognosis, particularly when typical features of usual interstitial pneumonia (UIP) are identified. The UIP-centric imaging approach emphasized in this review is justified by the prognostic significance of UIP, the prevalence of UIP in idiopathic pulmonary fibrosis, and its strong radiologic-pathologic correlation. In nonidiopathic pulmonary fibrosis ILD, progressive pulmonary fibrosis carries clinically significant prognostic and therapeutic implications. With growing evidence and the emergence of novel ILD-related concepts, recent updates of several imaging guidelines aim to optimize the approach to ILD. Artificial intelligence tools are promising adjuncts to the qualitative CT assessment and will likely augment the role of CT in the ILD realm.

Lung diseases represent one of the most prevalent health challenges globally, necessitating accurate diagnosis to improve patient outcomes. This work presents a novel deep learning-aided lung disease classification framework comprising three key phases: image acquisition, segmentation, and classification. Initially, chest X-ray images are taken from standard datasets. The lung regions are segmented using an Adaptive Recurrent Residual U-Net (AR2-UNet), whose parameters are optimised using Enhanced Pufferfish Optimisation Algorithm (EPOA) to enhance segmentation accuracy. The segmented images are processed using "Attention-based Densenet with Long Short Term Memory(ADNet-LSTM)" for robust categorisation. Investigational results demonstrate that the proposed model achieves the highest classification accuracy of 93.92%, significantly outperforming several baseline models including ResNet with 90.77%, Inception with 89.55%, DenseNet with 89.66%, and "Long Short Term Memory (LSTM)" with 91.79%. Thus, the proposed framework offers a dependable and efficient solution for lung disease detection, supporting clinicians in early and accurate diagnosis.

AI-driven scan time reduction is rapidly transforming medical imaging with benefits such as improved patient comfort and enhanced efficiency. A Dual Contrastive Learning Generative Adversarial Network (DCLGAN) was developed to predict full-time PET scans from shorter, noisier scans, improving challenges in imaging patients with movement disorders. 18F FP-CIT PET/CT data from 391 patients with suspected Parkinsonism were used [250 training/validation, 141 testing (hospital A)]. Ground truth (GT) images were reconstructed from 15-minute scans, while denoised images (DIs) were generated from 1-, 3-, 5-, and 10-minute scans. Image quality was assessed using normalized root mean square error (NRMSE), peak signal-to-noise ratio (PSNR), structural similarity index measure (SSIM), visual analysis, and clinical metrics like BPND and ISR for diagnosis of non-neurodegenerative Parkinson disease (NPD), idiopathic PD (IPD), and atypical PD (APD). External validation used data from 2 hospitals with different scanners (hospital B: 1-, 3-, 5-, and 10-min; hospital C: 1-, 3-, and 5-min). In addition, motion artifact reduction was evaluated using the Dice similarity coefficient (DSC). In hospital A, NRMSE, PSNR, and SSIM values improved with scan duration, with the 5-minute DIs achieving optimal quality (NRMSE 0.008, PSNR 42.13, SSIM 0.98). Visual analysis rated DIs from scans ≥3 minutes as adequate or higher. The mean BPND differences (95% CI) for each DIs were 0.19 (-0.01, 0.40), 0.11 (-0.02, 0.24), 0.08 (-0.03, 0.18), and 0.01 (-0.06, 0.07), with the CIs significantly decreasing. ISRs with the highest effect sizes for differentiating NPD, IPD, and APD (PP/AP, PP/VS, PC/VP) remained stable post-denoising. External validation showed 10-minute DIs (hospital B) and 1-minute DIs (hospital C) reached benchmarks of hospital A's image quality metrics, with similar trends in visual analysis and BPND CIs. Furthermore, motion artifact correction in 9 patients yielded DSC improvements from 0.89 to 0.95 in striatal regions. The DL-model is capable of generating high-quality 18F FP-CIT PET images from shorter scans to enhance patient comfort, minimize motion artifacts, and maintain diagnostic precision. Furthermore, our study plays an important role in providing insights into how imaging quality assessment metrics can be used to determine the appropriate scan duration for different scanners with varying sensitivities.

Advancements in coronary computed tomography angiography (CCTA) facilitated the transition from traditional histological approaches to comprehensive plaque burden assessment. Recent updates in the European Society of Cardiology (ESC) guidelines emphasize CCTA's role in managing chronic coronary syndrome by enabling detailed monitoring of atherosclerotic plaque progression. Limitations of conventional CCTA, such as spatial resolution challenges in accurately characterizing plaque components like thin-cap fibroatheromas and necrotic lipid-rich cores, are addressed with photon-counting detector CT (PCD-CT) technology. PCD-CT offers enhanced spatial resolution and spectral imaging, improving the detection and characterization of high-risk plaque features while reducing artifacts. The integration of artificial intelligence (AI) in plaque analysis enhances diagnostic accuracy through automated plaque characterization and radiomics. These technological advancements support a comprehensive approach to plaque assessment, incorporating hemodynamic evaluations, morphological metrics, and AI-driven analysis, thereby enabling personalized patient care and improved prediction of acute clinical events.

In pancreatic stereotactic body radiotherapy (SBRT), accurate motion management is crucial for the safe delivery of high doses per fraction. Intra-fraction tracking with magnetic resonance imaging-guidance for gated SBRT has shown potential for improved local control. Visualisation of pancreas (and surrounding organs) remains challenging in intra-fraction kilo-voltage (kV) imaging, requiring implanted fiducials. In this study, we investigate patient-specific deep-learning approaches to track the gross-tumour-volume (GTV), pancreas-head and the whole-pancreas in intra-fraction kV images. Conditional-generative-adversarial-networks were trained and tested on data from 25 patients enrolled in an ethics-approved pancreatic SBRT trial for contour prediction on intra-fraction 2D kV images. Labelled digitally-reconstructed-radiographs (DRRs) were generated from contoured planning-computed-tomography (CTs) (CT-DRRs) and cone-beam-CTs (CBCT-DRRs). A population model was trained using CT-DRRs of 19 patients. Two patient-specific model types were created for six additional patients by fine-tuning the population model using CBCT-DRRs (CBCT-models) or CT-DRRs (CT-models) acquired in exhale-breath-hold. Model predictions on unseen triggered-kV images from the corresponding six patients were evaluated against projected-contours using Dice-Similarity-Coefficient (DSC), centroid-error (CE), average Hausdorff-distance (AHD), and Hausdorff-distance at 95th-percentile (HD95). The mean ± 1SD (standard-deviation) DSCs were 0.86 ± 0.09 (CBCT-models) and 0.78 ± 0.12 (CT-models). For AHD and CE, the CBCT-model predicted contours within 2.0 mm ≥90.3 % of the time, while HD95 was within 5.0 mm ≥90.0 % of the time, and had a prediction time of 29.2 ± 3.7 ms per contour. The patient-specific CBCT-models outperformed the CT-models and predicted the three contours with 90th-percentile error ≤2.0 mm, indicating the potential for clinical real-time application.

The accurate and early evaluation of response to neoadjuvant chemotherapy (NAC) in breast cancer is crucial for optimizing treatment strategies and minimizing unnecessary interventions. While deep learning (DL)-based approaches have shown promise in medical imaging analysis, existing models often fail to comprehensively integrate spatial and temporal tumor dynamics. This study aims to develop and validate a spatiotemporal interaction (STI) model based on longitudinal MRI data to predict pathological complete response (pCR) to NAC in breast cancer patients. This study included retrospective and prospective datasets from five medical centers in China, collected from June 2018 to December 2024. These datasets were assigned to the primary cohort (including training and internal validation sets), external validation cohorts, and a prospective validation cohort. DCE-MRI scans from both pre-NAC (T0) and early-NAC (T1) stages were collected for each patient, along with surgical pathology results. A Siamese network-based STI model was developed, integrating spatial features from tumor segmentation with temporal dependencies using a transformer-based multi-head attention mechanism. This model was designed to simultaneously capture spatial heterogeneity and temporal dynamics, enabling accurate prediction of NAC response. The STI model's performance was evaluated using the area under the ROC curve (AUC) and Precision-Recall curve (AP), accuracy, sensitivity, and specificity. Additionally, the I-SPY1 and I-SPY2 datasets were used for Kaplan-Meier survival analysis and to explore the biological basis of the STI model, respectively. The prospective cohort was registered with Chinese Clinical Trial Registration Centre (ChiCTR2500102170). A total of 1044 patients were included in this study, with the pCR rate ranging from 23.8% to 35.9%. The STI model demonstrated good performance in early prediction of NAC response in breast cancer. In the external validation cohorts, the AUC values were 0.923 (95% CI: 0.859-0.987), 0.892 (95% CI: 0.821-0.963), and 0.913 (95% CI: 0.835-0.991), all outperforming the single-timepoint T0 or T1 models, as well as models with spatial information added (all p < 0.05, Delong test). Additionally, the STI model significantly outperformed the clinical model (p < 0.05, Delong test) and radiologists' predictions. In the prospective validation cohort, the STI model identified 90.2% (37/41) of non-pCR and 82.6% (19/23) of pCR patients, reducing misclassification rates by 58.7% and 63.3% compared to radiologists. This indicates that these patients might benefit from treatment adjustment or continued therapy in the early NAC stage. Survival analysis showed a significant correlation between the STI model and both recurrence-free survival (RFS) and overall survival (OS) in breast cancer patients. Further investigation revealed that favorable NAC responses predicted by the STI model were closely linked to upregulated immune-related genes and enhanced immune cell infiltration. Our study established a novel noninvasive STI model that integrates the spatiotemporal evolution of MRI before and during NAC to achieve early and accurate pCR prediction, offering potential guidance for personalized treatment. This study was supported by the National Natural Science Foundation of China (82302314, 62271448, 82171920, 81901711), Basic and Applied Basic Research Foundation of Guangdong Province (2022A1515110792, 2023A1515220097, 2024A1515010653), Medical Scientific Research Foundation of Guangdong Province (A2023073, A2024116), Science and Technology Projects in Guangzhou (2023A04J1275, 2024A03J1030, 2025A03J4163, 2025A03J4162); Guangzhou First People's Hospital Frontier Medical Technology Project (QY-C04).

Recently, a hepatic arterial infusion chemotherapy (HAIC)-associated combination therapeutic regimen, comprising HAIC and systemic therapies (molecular targeted therapy plus immunotherapy), referred to as HAIC combination therapy, has demonstrated promising anticancer effects. Identifying individuals who may potentially benefit from HAIC combination therapy could contribute to improved treatment decision-making for patients with advanced hepatocellular carcinoma (HCC). This dual-center study was a retrospective analysis of prospectively collected data with advanced HCC patients who underwent HAIC combination therapy and pretreatment contrast-enhanced ultrasound (CEUS) evaluations from March 2019 to March 2023. Two deep learning models, AE-3DNet and 3DNet, along with a time-intensity curve-based model, were developed for predicting therapeutic responses from pretreatment CEUS cine images. Diagnostic metrics, including the area under the receiver-operating-characteristic curve (AUC), were calculated to compare the performance of the models. Survival analysis was used to assess the relationship between predicted responses and prognostic outcomes. The model of AE-3DNet was constructed on the top of 3DNet, with innovative incorporation of spatiotemporal attention modules to enhance the capacity for dynamic feature extraction. 326 patients were included, 243 of whom formed the internal validation cohort, which was utilized for model development and fivefold cross-validation, while the rest formed the external validation cohort. Objective response (OR) or non-objective response (non-OR) were observed in 63% (206/326) and 37% (120/326) of the participants, respectively. Among the three efficacy prediction models assessed, AE-3DNet performed superiorly with AUC values of 0.84 and 0.85 in the internal and external validation cohorts, respectively. AE-3DNet's predicted response survival curves closely resembled actual clinical outcomes. The deep learning model of AE-3DNet developed based on pretreatment CEUS cine performed satisfactorily in predicting the responses of advanced HCC to HAIC combination therapy, which may serve as a promising tool for guiding combined therapy and individualized treatment strategies. Trial Registration: NCT02973685.